Inflammatix Receives Breakthrough Device Designation from FDA for TriVerity™
Regulatory Milestone Designed to Expedite Path to FDA Clearance and CMS Coverage click to read more
Host Response Diagnostics
Delivering precision medicine on demand
Our immune system has developed targeted responses to different types of infections and other diseases over millions of years. We are developing an assay to rapidly measure this immune response using proprietary machine-learning algorithms to generate clinically actionable results. Faster diagnostics may support faster and smarter care decisions, and better patient outcomes.
Validated in numerous independent cohorts involving thousands of patients and published in leading medical journals, Inflammatix is developing an innovative point-of-care platform and test to aid in the diagnosis of acute infection and sepsis by measuring the patient’s immune response to bacteria and viruses.
Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Our tests are addressing significant clinical needs in acute infection and sepsis diagnosis that affect millions of people
Products in development, not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Based on US CDC numbers. Numbers also referenced from Martin, NEJM 2003; Donnelly, Antimicrob. Ag Chemo 2013; Hasegawa, PIDJ 2015; Goto, J Am Ger Soc 2016; Magill, NEJM 2014; Horeczko, West JEM 2014; Fleming-Dutra, JAMA 2016.
In the News
Recent notable news stories
Inflammatix sepsis test scores FDA breakthrough device designation
November 28, 2023
Inflammatix Aims for 2024 Launch of 30-Minute Sepsis and Acute Infection Test
November 28, 2023
Your medical devices are getting smarter. Can the FDA keep them safe?
October 9, 2023
Point-of-care testing for infectious diseases in emergency settings
Inflammatix is reimagining diagnostics by developing rapid tests that read the immune system to resolve major clinical and public health challenges. Our initial focus is on acute bacterial and viral infections, and sepsis.
We’re seeking teammates with expertise, curiosity and passion for solving clinical challenges with a focus on patient outcomes. If that sounds like you, check out our Careers Page.